Cell Response and Regulation Program (Project-002)

细胞反应和调节程序 摘要 细胞反应与调节(CRR)计划是一个以实验室为基础的基础科学计划，重点是 破译与癌症有关的细胞机制。CRR的实验方法包括从生物化学到 来处理病人的组织。CRR发现科学支持亨斯迈癌症研究所对遗传学的关注 和个性化肿瘤学，通过提供对癌症途径的洞察作为新的基础 解决关键的临床问题。CRR成员的基本发现与癌症领域高度相关 预防、靶标识别、生物标记物开发、预后、诊断和治疗。 CRR研究集中在1)调节细胞周转的重要机制；2)异常信号 与癌症和耐药有关；3)细胞黏附、细胞迁移和转移。世界银行的一项主要资产 该计划是开发强大的癌症临床前模型，包括斑马鱼的神经脊模型- 衍生肿瘤和乳腺癌、肺癌、胰腺癌、脑癌和皮肤癌的小鼠模型，其中肿瘤是 在生理学的背景下诱导从头开始。CRR成员还与临床同事合作开发 异种移植模型，忠实地概括了患者来源的癌症的组织学和生物学行为。 这一资助期的主要成就包括更好地了解 执行细胞分裂，阐明参与上皮内稳态和迁移的信号通路，以及 发现一种新的乳腺癌生物标记物，它是骨髓瘤耐药的关键介质，以及 驱动脑瘤和黑色素瘤转移的因素。基本的CRR发现正在导致早期阶段 乳腺癌和黑色素瘤的临床试验，并影响了结肠癌的化学预防试验。 CRR由医学博士Douglas Grossman和博士Katharine Ullman共同领导，有26名成员来自 犹他大学三个学院的12个系，包括五名战略上的新成员 被招募了。值得注意的是，27%的CRR成员要么是医学博士，要么是医学博士，这带来了额外的临床视角。在……里面 2013年，CRR成员在癌症研究项目上的年度总资金为980万美元，其中34%来自NCI (比2008年的11%增长了两倍)。自2009年7月以来，获得了16项新的合作赠款，CRR研究 212种出版物(18%是计划内协作，37%是计划间协作)报告了这一点。所有正式成员 (100%)有同行评审的资金，许多人获得了杰出奖项。 癌症中心通过提供最先进的设施、共享的 资源、方案资金和对招聘的支持。在未来五年，CRR计划将 通过促进科学家之间富有成效的互动，继续促进以癌症为重点的协同研究 和临床医生，并培育具有临床应用潜力的基于CRR的研究发现。

CELL RESPONSE AND REGULATION PROGRAM ABSTRACT The Cell Response and Regulation (CRR) Program is a laboratory-based basic science program focused on deciphering cellular mechanisms involved in cancer. CRR's experimental approaches range from biochemistry to work with patient tissues. CRR discovery science supports Huntsman Cancer Institute's focus on genetics and individualized oncology by providing insights into cancer pathways that serve as new foundations to address critical clinical issues. CRR members' basic discoveries are highly relevant to the areas of cancer prevention, target identification, biomarker development, prognostics, diagnostics, and therapy. CRR Research focuses on mechanisms important in 1) regulation of cell turnover; 2) aberrant signaling in cancer and drug resistance; and 3) cell adhesion, cell migration, and metastasis. A major asset of the Program is the development of robust preclinical models of cancer, including zebrafish models of neural crest- derived tumors and mouse models of breast, lung, pancreatic, brain, and skin cancers, in which tumors are induced de novo in a physiologic context. CRR members also collaborate with clinical colleagues to develop xenograft models that faithfully recapitulate the histology and biologic behavior of patient-derived cancers. Major achievements in this funding period include improved understanding of the machinery that executes cell division, elucidation of signaling pathways involved in epithelial homeostasis and migration, and identification of a new biomarker for breast cancer, a critical mediator of drug resistance in myeloma, and factors that drive brain tumor and melanoma metastasis. Basic CRR discoveries are leading to early phase clinical trials in breast cancer and melanoma and have impacted a chemoprevention trial in colon cancer. Co-Led by Douglas Grossman, MD, PhD, and Katharine Ullman, PhD, CRR has 26 members from 12 University of Utah departments in three colleges, including five new members who were strategically recruited. Notably, 27% of CRR members are either MD/PhDs or MDs, bringing added clinical perspective. In 2013, CRR members had $9.8M in annual total funding for cancer research projects, including 34% from NCI (tripled from 11% in 2008). Since July 2009, 16 new collaborative grants were obtained, and CRR research was reported in 212 publications (18% intra- and 37% inter-programmatic collaborations). All full members (100%) have peer-reviewed funding, and many have received distinguished awards. The Cancer Center enhances the Program's goals by providing state-of-the-art facilities, Shared Resources, programmatic funds, and support for recruitments. Over the next five years, the CRR Program will continue to foster synergistic cancer-focused research by facilitating productive interactions between scientists and clinicians, and to cultivate CRR-based research discoveries with potential for clinical application.